Core Viewpoint - The company, Beijing Baipusi Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, indicating a strong performance in the biotechnology sector. Group 1: Financial Performance - As of June 30, 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38% [2] - The net profit attributable to shareholders reached 83.80 million yuan, with a year-on-year increase of 47.81% [2] Group 2: Shareholder and Market Activity - On September 25, 2023, the company's stock price increased by 3.43%, with a trading volume of 271 million yuan [1] - The number of shareholders increased to 11,700, up by 10.85% compared to the previous period [2] - The average number of circulating shares per shareholder decreased by 9.79% to 7,711 shares [2] Group 3: Financing and Margin Trading - On September 25, 2023, the company had a net financing purchase of 10.03 million yuan, with a total financing balance of 113 million yuan, accounting for 1.08% of the market capitalization [1] - The company’s margin trading balance is at a high level, exceeding the 90th percentile over the past year [1] Group 4: Dividend Distribution - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed in the last three years [3] Group 5: Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 5.9863 million shares, an increase of 3.7571 million shares from the previous period [3] - The sixth-largest circulating shareholder, China Europe Medical Health Mixed A, holds 3.2163 million shares, an increase of 0.5904 million shares [3]
百普赛斯9月25日获融资买入2904.66万元，融资余额1.13亿元